- Home
- CWEN vs SRRK Comparison
CWEN vs SRRK Comparison
Compare CWEN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | SRRK |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CWEN | SRRK |
|---|---|---|
| Price | $37.49 | $44.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $41.25 | ★ $55.10 |
| AVG Volume (30 Days) | 853.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.19 | N/A |
| Revenue Next Year | $7.78 | $449.79 |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.63 | $22.71 |
| 52 Week High | $41.51 | $49.82 |
Technical Indicators
Market Signals| Indicator | CWEN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 47.14 |
| Support Level | $35.91 | $41.54 |
| Resistance Level | $41.51 | $48.31 |
| Average True Range (ATR) | 1.06 | 2.21 |
| MACD | -0.35 | -0.23 |
| Stochastic Oscillator | 21.15 | 42.09 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.